{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:47:43Z","timestamp":1771868863557,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VHRM"],"DOI":"10.2147\/vhrm.s26482","type":"journal-article","created":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T21:43:28Z","timestamp":1327441408000},"page":"45","source":"Crossref","is-referenced-by-count":4,"title":["New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders"],"prefix":"10.2147","author":[{"given":"Christine","family":"Winchester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,1]]},"container-title":["Vascular Health and Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=11903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:07:51Z","timestamp":1477850871000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/new-oral-antithrombotics-focus-on-dabigatran-an-oral-reversible-direct-peer-reviewed-article-VHRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/vhrm.s26482","relation":{},"ISSN":["1178-2048"],"issn-type":[{"value":"1178-2048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}